Vitrafy Life Sciences Ltd. · ASX:VFY
Vitrafy Life Sciences — Investor Presentation (January 2026)
6 slides from Vitrafy Life Sciences's investor presentation, Jan 15, 2026
Slide 1: IMV Strategic Partnership
IMV Strategic Partnership 15 January 2026 Vitrafy Life Sciences Limited (ASX: VFY) ACN 622 720 254 vitrafy.com Strictly Private & Confidential 1
Slide 2: Overview
Overview Strategic Commercial Product Alignment Growth Catalyst Agreement Vitrafy has entered Partnership to integrate Accelerated access to the into a strategic, With global, animal Vitrafy’s cryopreservation animal market at scale, for reproduction leader, IMV commercial Technologies (“IMV”). tech
Slide 3: Introduction to IMV
Introduction to IMV IMV is the market leader in animal reproduction market. Established Market Leader • Founded in 1963 Trusted Partner • Involved in half a billion • Experts in artificial artificial insemination Growth Focused insemination, semen processes each year preservation, and reproductive d
Slide 4: The Agreement
The Agreement Combining Vitrafy’s next-generation cryopreservation technology with IMV’s globally recognised platform to set a new industry benchmark. • Exclusive, 12-month strategic collaboration to co-develop a solution that brings the strengths of both organisations - expertise, product portfolio
Slide 5: In summary
In summary • Validates the use of Vitrafy’s technology in a commercial setting • Leverages IMV’s significant expertise in this market • Provides access to a significant share of the animal reproduction market • Allows Vitrafy to focus on the high growth human health market in the US 5
Slide 6: Q&A
Q&A 6
Vitrafy Life Sciences — Investor Presentation (January 2026) on 6ix